Most Recent
Two former barristers ordered to pay at least $21.7 million in damages and costs for their role in a fraudulent scheme to pocket a windfall from the Banksia Securities class action have filed for bankruptcy.
The applicant in a class action against self-managed superfund provider Dixon Advisory wants to intervene in ASIC's proceedings, which the company agreed to resolve for $7.2 million, saying any penalty in the case should be held by the court until the resolution of the class action.
IP Australia has won its appeal of a judge’s decision to allow four Aristocrat patents for its popular Lightning Link electronic poker machine to proceed to grant, with the Full Court finding the invention merely implemented an abstract idea on a computer and was not patentable.
A law firm that has filed seven class actions on behalf of casual coal mine workers is looking to discontinue two of those cases, after the High Court dealt them a serious blow by finding that those who work regular shifts are not entitled to paid leave and other entitlements under the Fair Work Act.
A judge has given the green light to expanded misconduct allegations in a shareholder class action against IOOF, including claims of insider trading and front-running.
A judge has indicated he will approve the 'very low' GetSwift class action settlement because the company appeared to be broke, but the law firm behind the case has been pulled up by the court for a previous costs estimate that has blown out by $3 million.
A judge has declined a contradictor's calls to send an application for a common fund order in a class action against 7-Eleven, which recently settled for $98 million, to the Full Court.
A judge has scolded Slater & Gordon and two Westpac subsidiaries for a "disgraceful" privilege spat in a class action over allegedly excessive superannuation fees that he said had "gone badly off the rails".
A former partner at accounting firm Pitcher Partners has told a court that he had issues working with Ernst & Young on an audit of law firm Slater & Gordon, calling the Big 4 firm "uncooperative".
Five years into a preliminary discovery application for a potential patent infringement lawsuit over a biosimilar of its Enbrel medication, Pfizer has partially succeeded in obtaining further documents from Samsung Bioepis.